{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-057152","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.513276+00:00","generated_at":"2026-06-15T13:19:22.198748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Theravance Biopharma Q1 2023 net loss narrows to $22.1M; YUPELRI sales up 8% to $47M","bullets":["Q1 GAAP net loss from continuing ops $22.1M vs $40.3M; non-GAAP net loss $14.9M vs $25.2M.","YUPELRI net sales (Viatris) $47M, +8% YoY; Theravance's 35% share $16.4M.","$215M of $325M buyback completed; $110M remaining; on track to finish by year-end.","CYPRESS Phase 3 study of ampreloxetine in MSA-nOH actively recruiting; enrollment expected H2 2024.","Jim Kelly (Weiss Asset Mgmt) appointed to Board; TRELEGY milestone $50M if 2023 global sales ≥ $2.9B."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-057152","json":"https://secwatch.observer/filing/0001104659-23-057152.json","markdown":"https://secwatch.observer/filing/0001104659-23-057152.md","text":"https://secwatch.observer/filing/0001104659-23-057152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923057152/0001104659-23-057152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923057152/tm2314872d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:19:22.198748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a867199973c778d5a584e82b84c363101109927","claim":"Theravance Biopharma, Inc. reported the first quarter of 2023 results: revenue $10.4 million.","evidence_excerpt":"Total revenue for the first quarter of 2023 was $10.4 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923057152/0001104659-23-057152-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Revenue","value":"$10.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}